Provider review
Oak Longevity tirzepatide review
What Oak Longevity charges, what is included, who prescribes, which pharmacy fills it, where it operates — and how much of that we confirmed ourselves rather than took from the website.
This is an independent assessment of Oak Longevity's tirzepatide program against our published 100-point rubric. It separates what the provider states from what we verified. No pricing, scoring or state data has been captured yet, so nothing below is presented as a finding. Verification status appears beside every field.
What is distinctive about this programme
The lowest reported semaglutide figure, with a state exclusion
At $133 a month for compounded semaglutide, Oak Longevity sits below every other provider in our dataset including NexLife (opens nexlife.us in a new tab)'s verified $145. That is a genuine price position, and it comes with an explicit constraint: the programme is not available in California.
That exclusion is itself informative. State-specific unavailability generally reflects prescriber licensure or nonresident pharmacy shipping registration, which means the provider is being accurate about a limit rather than making a blanket national claim. Several competitors claim availability in all fifty states without publishing any state-by-state evidence.
No subscription, flat across dosages
Oak Longevity is reported as charging no membership and holding price across dosages. For a patient expecting to titrate to a maintenance dose, that combination removes the two most common sources of cost escalation in this category.
The multi-month condition
The headline rates require a multi-month plan. Month-to-month is reported at roughly $167 to $199 for semaglutide and $233 to $299 for tirzepatide — a 25% to 50% premium. The tirzepatide month-to-month range overlaps brand Zepbound's $299 starter price direct from LillyDirect, which is worth knowing before committing.
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Semaglutide injectable | $133 | Provider-reported |
| Tirzepatide injectable | $199 | Provider-reported |
Where it holds up
- Lowest reported standard compounded semaglutide price in our dataset at $133
- No subscription or membership fee reported
- Flat pricing across all dosages
- Publishes an explicit state exclusion rather than claiming blanket national availability
Where it does not
- Not available in California
- Headline rates require a multi-month plan; month-to-month is 25–50% higher
- Tirzepatide month-to-month overlaps brand Zepbound's manufacturer-direct price
- Figures are third-party reported and not yet captured by us
| Field | Position |
|---|---|
| Membership | Separate and required |
| Dose structure | Flat across covered doses |
| Lowest captured figure | $133/mo, prepaid term |
| Evidence status | Third-party reported, pending our own capture |
| Pharmacy named to us | No — provider-reported only |
Show this figure as a table
| Item | Points | Evidence |
|---|---|---|
| Pricing transparency and all-in value | 25 pts | Verified |
| Clinical oversight and care continuity | 20 pts | Verified |
| Pharmacy traceability and quality disclosures | 15 pts | Verified |
| Regulatory clarity and consumer disclosures | 15 pts | Verified |
| State access and operational reliability | 10 pts | Verified |
| Cancellation, billing and support transparency | 10 pts | Verified |
| Evidence quality and data availability | 5 pts | Verified |
Pricing, all-in
Plan total and monthly equivalent are calculated by us from the provider's published figures, using the same formula applied to every provider on this site. A price is only a price once the required fees are inside it.
| Provider | Program | Formulation | Dose coverage | Medication | Required fees | All-in monthly | Price type | Evidence | Captured |
|---|---|---|---|---|---|---|---|---|---|
| Oak Longevity | prepaid | compounded injectable | flat at all covered doses | $199 | not verified | $199 | Commitment tier | Provider-reported | 2026-07-06 |
| Oak Longevity | prepaid | compounded injectable | flat at all covered doses | $133 | not verified | $133 | Commitment tier | Provider-reported | 2026-07-06 |
How this sits against the market
Show this figure as a table
| Item | Value | Evidence |
|---|---|---|
| Found | $169 | Provider-reported |
| NexLife (opens nexlife.us in a new tab) | $186 | Verified |
| Oak Longevity | $199 | Provider-reported |
| Shed | $245 | Provider-reported |
| Mochi Health | $278 | Provider-reported |
| Enhance.MD | $280 | Provider-reported |
| Eden | $298 | Provider-reported |
| Noom Med | $299 | Provider-reported |
| TrimRx | $349 | Provider-reported |
| MEDVi | $399 | Verification pending |
| bmiMD | $399 | Provider-reported |
Show this figure as a table
| Component | Amount |
|---|---|
| Medication | not captured |
| Membership | not captured |
| Shipping | not captured |
| Dose surcharge | not captured |
| Consultation | not captured |
| Labs | not captured |
| All-in total | not captured |
| Cost component | Inside the advertised figure? | Charged anyway? |
|---|---|---|
| Medication | yes | yes |
| Membership or program fee | no | not verified |
| Shipping | no | not verified |
| Higher-dose surcharge | no | not verified |
| Initial consultation | no | not verified |
| Required laboratory work | no | not verified |
| Cancellation or restocking terms | no | not verified |
This chart stays empty until two or more dated captures exist. Historical values are never estimated or backfilled from a provider's current page.
Show this figure as a table
| Item | This provider | Category median |
|---|---|---|
| All-in monthly | not captured | not captured |
| Membership fee | not captured | not captured |
| Rubric score | not captured | not captured |
What is included, and what is not
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Where it operates
State availability is verified against the provider's own checkout or a support confirmation, state by state, with a capture date. A provider serving forty states is not nationwide, and we do not describe it that way.
Show this figure as a table
| Status | Records | Share |
|---|---|---|
| Researched and verified | 0 | 0% |
| Not yet researched | 51 | 100% |
Clinical model
- Who prescribes: employed clinicians, a contracted medical group, or a partner network. Name the entity.
- Whether an initial synchronous visit occurs, and whether the state requires one.
- Follow-up cadence, escalation route and adverse-event handling.
- Continuity: what happens to a patient when their prescriber leaves the platform.
Pharmacy and fulfilment
- Named fulfilling pharmacy or outsourcing facility, and its registration class (503A or 503B).
- Verify any accreditation claim directly with the accrediting body, not with the provider.
- Testing disclosures: what is tested, by whom, and whether a certificate is available to patients.
- Cold-chain handling and what happens to a shipment that arrives warm.
Billing, cancellation and support
- Auto-renew behaviour and the exact cancellation route, captured as a screenshot.
- Refund terms for unopened, undelivered and unused medication.
- Published support channels and any stated response time — then test it.
What changed
Show this figure as a table
| No events recorded. |
- no entriesNothing has changed yet because nothing has been published yet. Entries appear here when a verified figure, score or conclusion changes, never for a typo fix.
How this compares to the category
Once enough providers are scored, this section reports where Oak Longevity sits against the median for each rubric category, not against a hand-picked competitor.
Questions readers actually ask
Is Oak Longevity the cheapest option?
We will not answer that until the all-in figures are captured for the whole comparison set. A cheapest claim needs a defined comparison group, a stated program type and a capture date, or it is just an adjective.
Is this review sponsored?
No. No provider pays for coverage, placement, a score or a link, and providers do not see a review before it publishes.
Is compounded tirzepatide the same as Zepbound?
No. Compounded preparations are not FDA-approved products and there is no generic tirzepatide. Approval of the brand product does not extend to a compounded preparation.
Related on this site
- All provider reviewsProviders
- NexLife Tirzepatide ReviewProviders
- Ro Body Tirzepatide ReviewProviders
- Hims & Hers Tirzepatide ReviewProviders
- Provider ranking methodologyCore & Trust
- GLP-1 total cost calculatorTools
- Download the pricing recordsData
- Questions to Ask a GLP-1 ClinicianTools
- Provider and Study Source LedgerData
- Privacy PolicyCore & Trust
GLP-1 Tirzepatide Review. “Oak Longevity Tirzepatide Review.” S.J Partners LLC, 2026-07-24. https://glp1tirzepatidereview.com/providers/oak-longevity/
When quoting a figure, include the capture date shown beside it rather than the date you read this page. A price without its capture date is not a usable citation.